Saint Peter’s University Hospital is significantly advancing its lung cancer diagnostic capabilities with the introduction of Ion Robotic Bronchoscopy technology. This minimally invasive system is designed to reach small, early-stage lesions deep within the lungs with unprecedented precision and stability, offering the potential to save lives.
Lung cancer remains a formidable challenge, with an estimated 226,650 new cases projected in the U.S. this year. The key difficulty is that most cancers are detected late because early-stage tumors are often small, lack symptoms, and are located in peripheral areas of the lung, making them difficult to access with standard tools.
Traditional bronchoscopy can have a diagnostic yield as low as 30 to 40 percent for these small, peripheral lesions. When traditional methods fail, patients must often undergo more invasive procedures, such as needle biopsies through the chest wall—which carries risks like lung collapse (pneumothorax)—or surgical biopsies that extend recovery times.
Ion Robotic Bronchoscopy is designed to overcome these limitations. The technology allows clinicians to navigate to lesions in all 18 segments of the lung, enabling earlier diagnosis and treatment.
“Time is on your side when lung cancer is detected early because early-stage cancers are usually localized. This significantly increases the odds for a cure,” Dr. Douglas Frenia, a pulmonologist at Saint Peter’s University Hospital, who performed the hospital’s first successful procedure in October, said. That initial robotic bronchoscopy successfully diagnosed an early-stage lung cancer, and the patient has since been referred for curative resection.
The procedure is minimally invasive and begins with a high-resolution CT scan to create a detailed 3D map of the patient’s lungs. Using this map, the pulmonologist plots a precise pathway to the lesion.
During the procedure, a thin, guided, flexible catheter is navigated through the lung’s complex airways.
“The catheter can articulate up to 180 degrees in any direction, maintaining stability as it moves deeper into smaller airways,” Dr. Amar Bukhari, chief of the Division of Pulmonary, Critical Care and Sleep Medicine at Saint Peter’s University Hospital, said. “Real-time navigation feedback ensures accurate positioning, and advanced X-ray imaging confirms that the biopsy tool is exactly where it needs to be.”
The benefits of the Ion Robotic Bronchoscopy are centered on patient safety and faster intervention:
-
Less Invasive: The procedure is performed through the mouth without the need for surgical incisions.
-
Lower Complication Rates: The risk of lung collapse (pneumothorax) is significantly lower than with transthoracic needle biopsy.
-
Faster Recovery: Most patients are able to go home the same day.
-
Faster Diagnosis: Eliminating diagnostic delays ensures patients receive treatment earlier when needed, which is critical since the five-year survival rate for localized lung cancer is about 67 percent, compared with 12 percent once the disease has spread.
“Ion Robotic Bronchoscopy gives our pulmonology team the ability to reach lung nodules that most technologies can only monitor,” Bukhari sid. “Now we can intervene earlier, reduce procedural risks, and shorten the patient’s path to diagnosis.”
Saint Peter’s is urging eligible patients to schedule a low-dose CT lung screening. Eligibility criteria include adults aged 50 to 80 (or 50 to 77 for Medicare) who have a 20 pack-year smoking history and are either current smokers or quit within the past 15 years.
